Abstract Library

#647 Reducing the Risk of Tuberculosis Reactivation when Administering Everolimus for a Pancreatic Neuroendocrine Tumor: A Case Report

Introduction: Everolimus can potentially reactivate tuberculosis (TB) through immunosuppression. This was recently reported to have occurred in a kidney transplant recipient. To date, no clear strategy has been developed for reducing the risk of TB reactivation during everolimus treatment.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Tamura T, Nakazuru S, Sakane S, Iwasaki R, Iwasaki T,

Keywords: everolimus, NET, LTBI,

#626 Preliminary Results of a Nationwide Survey of Pancreatic Neuroendocrine Tumors in von Hippel–Lindau Disease in Japan

Introduction: von Hippel–Lindau disease (VHL) is an intractable disease characterized by various tumors including pancreatic neuroendocrine tumors (PNET).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Igarashi H, Ito T, Nishimori I, Tamura K, Yamasaki I,

Keywords: von Hippel–Lindau disease, pancreatic neuroendocrine tumors,

#597 Primary Hepatic Neuroendocrine Carcinomas Treated with a Combination of Cisplatin and Etoposide as First-Line Chemotherapy: Two Case Reports

Introduction: Because primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare, a standard regimen has not yet been established. However, the combination of etoposide and cisplatin (EP) has been widely used to treat PHNEC.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Nakazuru S, Iwasaki R, Tamura T, Iwasaki T, Hasegawa H,

Keywords: liver, neuroendocrine carcinoma, chemotherapy,